Streetbeat News

Products Services

YTEN

Yield10 Bioscience, Inc. (NASDAQ:YTEN) has completed the harvest of a majority of the winter and spring Camelina grain produced under grower contracts in 2022/2023. The harvested grain is being delivered to an offtake partner for biofuel production, marking the establishment of the company's 'Camelina Seed Genetics to Biofuel' platform. This has allowed Yield10 to start generating revenue from Camelina grain delivery for the production of feedstock oil for sustainable transportation fuels. The company expects the revenue stream from sales of Camelina grain to be a significant contributor to its financial profile in the future.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:34 pm

ANIX

Anixa Biosciences, Inc. (NASDAQ:ANIX) has been granted an additional U.S. patent for its novel ovarian cancer vaccine technology. The patent covers nucleic acid-based delivery of the vaccine, which targets the extracellular domain of anti-Müllerian hormone receptor 2 (AMHR2-ED). Anixa is developing the technology in partnership with Cleveland Clinic and with support from the National Cancer Institute's PREVENT Program.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:34 pm

GILD

Gilead Sciences is set to present its latest innovative virology data on current and potentially transformative therapies for HIV and Covid-19 at IDweek 2023. The research reinforces the efficacy of Biktarvy in a broad range of people with HIV and highlights the potential impact of twice-yearly Lenacapavir on the future of HIV clinical care. The data also reinforces Veklury's strong safety profile and continued in vitro activity against new variants. Studies are also evaluating the utility of Obeldesivir as a potential treatment for COVID-19.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:32 pm

BRQS

Borqs Technologies, Inc. (NASDAQ:BRQS) is expanding its Internet of Things (IoT) device business in Africa, with potential annual sales of $30M. The company is developing smart IoT devices, primarily mobile phones, for the African market in partnership with a global financing company. The devices will be leased to local users through a local leasing company. The project could produce about 500,000 units per year.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:32 pm

ACRX

AcelRx Pharmaceuticals has received Investigational Device Exemption (IDE) approval from the FDA for its product Niyad, allowing it to advance to a single registration study.

Portfolio Pulse from Bill Haddad

October 03, 2023 | 12:31 pm

BDRX

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) has completed recruitment for cohort A of its Phase 1 study of MTX110 in patients with recurrent glioblastoma. The study is designed to assess the feasibility and safety of intermittent infusions of MTX110. The company plans to commence enrolment for cohort B upon approval by the study's Data Safety Monitoring Board, expected by the end of October 2023. Biodexa also plans to add two more investigational centres into the study by January 2024.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:31 pm

KA

Kineta has announced safety and biomarker data from its ongoing Phase 1/2 VISTA-101 clinical trial for KVA12123 monotherapy. The trial has cleared the first three monotherapy cohorts with no dose limiting toxicity and no consistent pattern of adverse events at any dose level. The clinical trial is advancing to higher monotherapy dose levels and in combination with Pembrolizumab. Initial monotherapy clinical efficacy data is anticipated in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:31 pm

GOOG

GOOGL

Google, a subsidiary of Alphabet Inc., is set to launch Android 14 alongside its new Pixel 8 series devices and Pixel Watch 2. The update, dubbed 'Android U', is expected to be available on October 4th for various Google Pixel devices. However, the Pixel 4a will not receive a stable Android 14 update, while the Pixel 8 and Pixel 8 Pro devices will have Android 14 pre-installed. The rollout of Android 14 coincides with Google's launch event.

Portfolio Pulse from Benzinga Neuro

October 03, 2023 | 12:29 pm

JNJ

SNY

Sanofi SA (SNY) and Janssen Pharmaceuticals, a unit of Johnson & Johnson (JNJ), have partnered to develop and commercialize a vaccine for extraintestinal pathogenic E. coli. The vaccine is currently in Phase 3 trials. Sanofi will pay J&J’s Janssen unit $175 million upfront and development and commercial milestones. A profit-share arrangement will exist in the U.S., EU4, and the U.K.

Portfolio Pulse from Vandana Singh

October 03, 2023 | 12:25 pm

ENVB

Enveric Biosciences has announced a milestone in its Psybrary portfolio of psychedelic-inspired molecules, surpassing 1,000 synthesized compounds. The company's proprietary artificial intelligence (AI) drug-discovery platform, PsyAI™, has accelerated the design of new chemical entities for specific applications in mental health management.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 12:19 pm